

Nurulimab Biosimilar - Research Grade

Product Code: ICH5717

More Information

Species Reactivity: Human

Target: CTLA4 α 1/2

Concentration: 5mg/ml

Isotype: IgG1 - kappa

Host: CHO Cells

product name H2: Nurulimab Biosimilar - Research Grade

Sequence: <https://www.imgt.org/mAb-DB/>

Buffer: ICH3002

UniProt: P09793;P16410

Shipping Conditions: Blue ice

background: CTLA-4 is a pivotal inhibitory checkpoint receptor that restrains T-cell activation, making it a cornerstone of immuno-oncology research. This research-grade human IgG1 kappa antibody is an unconjugated, non-therapeutic analog of nurulimab, produced in CHO cells against human CTLA4. Released for research use only, it is purified to a low-endotoxin standard appropriate for in vivo use and supplied in scalable milligram (mg) to gram (g) quantities for high-throughput, heavy-usage laboratories. It is a reliable reagent for checkpoint-blockade assays, T-cell functional studies, ADCC investigations, and preclinical tumor-immunity models. It delivers the consistency that bulk-consuming research programs require.

Purification Method: This monoclonal antibody was purified using Protein A

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.



Purity: >90% by SDS-PAGE

Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method

Storage: This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications: Functional Assays

Application Notes: This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Delivery Time: 3-4 weeks